Is Ascimini's English name asciminib?

Asciminib (Asciminib), whose English name is "asciminib", is the first FDA-approved treatment drug for chronic myelogenous leukemia (CML) that binds to the myristoyl group of ABL. This new mechanism of action, also known as STAMP inhibitors in the scientific literature, may help address drug resistance in patients with chronic myelogenous leukemia who have previously received two or more TKI therapies and overcome defective BCR-ABL1 gene mutations associated with overproduction of leukemia cells.

Asiminib has also been shown to limit off-target activity in preclinical studies. Novartis has initiated regulatory filings for Asiminib in many countries and regions around the world. Asiminib represents an important advance for patients with resistance and/or intolerance to currently available TKI therapies and is currently being studied in multiple lines of treatment for CML-CP. Specifically, the phase ASC4FIRST study (NCT04971226) is evaluating aceminib as first-line treatment and is in the recruitment phase.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminil sold overseas is very expensive, and the price of 20mg*60 oral tablets is about more than 20,000 US dollars (the price may fluctuate due to the exchange rate). There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.